Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02614859
Other study ID # GU-079
Secondary ID 15-1015
Status Completed
Phase Phase 2
First received
Last updated
Start date December 1, 2015
Est. completion date January 24, 2020

Study information

Verified date March 2022
Source Fox Chase Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Obesity and metabolic syndrome are prevalent among prostate cancer patients. Having an elevated insulin level in the blood is associated with a shorter median time to cancer progression and median overall survival in patients with an elevated PSA after prior treatment. Androgen deprivation therapy (ADT) with drugs like bicalutamide is frequently used in this patient population,with no proven benefit, which may increase mortality and morbidity.This study evaluates how metformin in combination with bicalutamide affects prostate cancer.


Description:

1 Cycle = 28 days = 4 weeks. Treatment will be administered on an outpatient basis ΣΏ Metformin starting dose is 500 mg BID, will be gradually increased to target dose of 1000mg BID. Treatment ARM A Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg daily, orally, continuously to the end of study (week 32). Treatment ARM B Cycles 1 - 2: In order to minimize gastrointestinal discomfort, metformin dosing will be ramped up over a period of 2 weeks. Metformin treatment will be started at 500 mg BID (Dose Level -2) and increased by an increment of 500 mg daily every week +/- 2 days provided no grade 2 or higher gastrointestinal toxicity is noted. If grade 2 or greater gastrointestinal toxicity occurs during the first 4 weeks of treatment, the subject will be evaluated every 2 weeks until resolution of toxicity to grade 0 or 1 and, then, the metformin dose will be increased to the next dose level. The target dose of metformin is 1000 mg BID.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date January 24, 2020
Est. primary completion date January 24, 2020
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: Ability to understand and the willingness to sign a written informed consent Male 18 years or older Histologically or cytologically confirmed diagnosis of prostate cancer Patient must have had previous treatment with definitive surgery or radiation therapy or cryoablation Patient may have prior salvage therapy (surgery, radiation or other local ablative procedures) within 6 months prior to randomization if the intent was for cure.Prophylactic radiotherapy to prevent gynecomastia within 4 weeks prior to randomization is allowed BMI > 25 at study entry Patient may have had prior neoadjuvant and/or adjuvant therapy (chemotherapy, vaccines or experimental agents) within 4 weeks prior to randomization, if the PSA rise and PSADT were documented after the testosterone level was > 150ng/dL. Patient must have hormone-sensitive prostate cancer as evident by a serum total testosterone level > 150 ng/dL within 12 weeks prior to randomization. PSA must be < 30 ng/mL at study entry Patient may not have had therapy modulating testosterone levels (such as luteinizing hormone,releasing-hormone agonists/antagonists and antiandrogens) within 1 year prior to randomization, unless it was in the neoadjuvant and/or adjuvant setting Patient must have evidence of biochemical failure after primary therapy and subsequent progression. Biochemical failure is declared when the PSA reaches a threshold value after primary treatment and it differs for radical prostatectomy or radiation therapy. 1. For radical prostatectomy the threshold for this study is PSA = 0.2ng/mL 2. For radiation therapy the threshold is a PSA rise of 2 ng/mL above the nadir PSA achieved post radiation with or without hormone therapy (2006 RTOG-ASTRO Consensus definition). 3. PSA progression requires a PSA rise above the threshold measured at any time point since the threshold was reached. PSA doubling time between 3 and 9 months. PSA calculation requires two consecutive PSA rises (PSA2 and PSA3) above the threshold PSA (total 3 PSA values); PSA2 and PSA3 must be obtained within 12 months of study entry. All baseline PSAs should be obtained at the same reference lab. Patient's PSA doubling time must be calculated using the following formula (http://www.mskcc.org/nomograms/prostate/psa doubling-time): ECOG performance status less than or equal to 2 Ability to swallow the study drugs Subjects must have normal organ and marrow function as defined below: 1. Absolute neutrophil count greater than or equal to 1,000/mL 2. Hemoglobin greater than or equal to 10 g/dL 3. Platelets greater than or equal to 100,000/mL 4. Total bilirubin within normal institutional limits 5. AST(SGOT)/ALT(SGPT) less than or equal to 1.5 X institutional ULN 6. Creatinine clearance greater than or equal to 60 mL/min/1.73 m2 7. Hgb A1c = 6.5 Exclusion Criteria: Evidence of metastatic disease on imaging studies (CT and/or bone scan) Diagnosis of diabetes mellitus defined as 1. Fasting blood glucose > 126 mg/dl or, 2. Random blood glucose > 200 mg/dl 3. Hemoglobin A1C > 6.5% Need for treatment with any conventional modality for prostate cancer (surgery, radiation therapy, and hormonal therapy) Prior hormonal therapy for recurrent prostate cancer (hormonal therapy given in a neoadjuvant or adjuvant setting and greater than 6 months before entry is acceptable) Treatment within the last 30 days with any investigational drug Radiation therapy within prior 6 months (prophylactic radiotherapy to prevent gynecomastia within 4 weeks prior to randomization is allowed) Known hypersensitivity to metformin Prior history of lactic acidosis Any history of myocardial infarction in the past 12 months Subjects who consume more than 3 alcoholic beverages per day Subjects with serious intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or other nonmalignant medical or psychiatric illness that is uncontrolled or whose control may be jeopardized by the complications of this therapy or may limit compliance with the study requirements (at the discretion of the investigator) Patient with previous or concurrent malignancy. Exceptions are made for patients who meet any of the following conditions: Basal cell or squamous cell carcinoma of the skin or prior malignancy that has been adequately treated and patient has been continuously disease free for = 2 years. Subjects currently treated with metformin and/or bicalutamide or who have been treated with metformin and/or bicalutamide in the past 6 months. Subjects who have taken 5a-reductase inhibitors (finasteride or dutasteride), saw palmetto, or PC-SPES within the last 6 weeks are ineligible. Subjects will be eligible for the study after the wash out period of 6 weeks.

Study Design


Intervention

Drug:
Observation and Bicalutamide
Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg daily, orally, continuously to the end of study (week 32).
Metformin and Bicalutamide
Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID

Locations

Country Name City State
United States National Cancer Institute Bethesda Maryland
United States Fox Chase Cancer Center - Philadelphia Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Fox Chase Cancer Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

Bilusic M, Toney NJ, Donahue RN, Wroblewski S, Zibelman M, Ghatalia P, Ross EA, Karzai F, Madan RA, Dahut WL, Gulley JL, Schlom J, Plimack ER, Geynisman DM. A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Biochemical Response Rate Based on PSA Participants with undetectable PSA after 32 weeks 32 weeks
Secondary PSA Decline = 85% at 32 Weeks Number of patients with PSA decline = 85% after 32 weeks 32 Weeks
Secondary PSA Decline Number of patients with PSA decline after 8 weeks (observation vs metformin) 8 Weeks
Secondary Median PSA Decline Median PSA decline after 8 weeks % (range) 8 weeks
Secondary BMI Decline After 32 Weeks Number of patients with BMI decline after 32 weeks 32 Weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT05191017 - Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Phase 1/Phase 2
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Completed NCT03031418 - Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)
Completed NCT01639859 - Assessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci N/A
Not yet recruiting NCT06406803 - The Impact of Physical Activity Versus Dietary Energy Restriction on Tumour and Muscle Protein Synthesis in Prostate Cancer Patients N/A
Completed NCT02362464 - Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 Phase 2
Enrolling by invitation NCT05844761 - Real-time Motion Management During Prostate and Lung Radiotherapy N/A
Completed NCT03442075 - Pain Comparison Whit Visual Analog Scale (EVA) Between Four Analgesic Methods During Trans Rectal Prostatic Biopsy
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Completed NCT03444532 - Feasibility Study Testing a Sleep Intervention in Prostate Cancer Patients With Insomnia N/A
Recruiting NCT05600400 - Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer N/A
Recruiting NCT04887935 - Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer Phase 1
Completed NCT02235142 - Prostatic Cancer Versus Androgen Deficiency N/A
Recruiting NCT06318559 - Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention N/A
Completed NCT01477749 - Sipuleucel-T Manufacturing Demonstration Study Phase 2
Active, not recruiting NCT03632980 - Dynamic Focusing Evaluation for Prostate Cancer Treatment N/A
Recruiting NCT04319783 - Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA Phase 2
Recruiting NCT04258813 - Onco-primary Care Networking to Support TEAM-based Care N/A
Recruiting NCT05361798 - T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy Phase 2